HOUSTON--(BUSINESS WIRE)--Texas Heart Institute at St. Luke’s Episcopal Hospital reaffirms its ongoing commitment to heart recovery by highlighting its recent participation in the FDA-approved PROTECT I patient safety trial for Abiomed’sTM Impella® 2.5 catheter-based heart pump device.
